Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
4D Molecular Therapeutics Inc has a consensus price target of $39.55 based on the ratings of 12 analysts. The high is $81 issued by Goldman Sachs on February 7, 2024. The low is $13 issued by SVB Securities on April 13, 2023. The 3 most-recent analyst ratings were released by Chardan Capital, Leerink Partners, and HC Wainwright & Co. on September 19, 2024, respectively. With an average price target of $37 between Chardan Capital, Leerink Partners, and HC Wainwright & Co., there's an implied 255.43% upside for 4D Molecular Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for 4D Molecular Therapeutics (NASDAQ:FDMT) was reported by Cantor Fitzgerald on September 23, 2024. The analyst firm set a price target for $0.00 expecting FDMT to fall to within 12 months (a possible -100.00% downside). 22 analyst firms have reported ratings in the last year.
The latest analyst rating for 4D Molecular Therapeutics (NASDAQ:FDMT) was provided by Cantor Fitzgerald, and 4D Molecular Therapeutics downgraded their neutral rating.
The last upgrade for 4D Molecular Therapeutics Inc happened on November 15, 2022 when Goldman Sachs raised their price target to $68. Goldman Sachs previously had a neutral for 4D Molecular Therapeutics Inc.
The last downgrade for 4D Molecular Therapeutics Inc happened on September 23, 2024 when Cantor Fitzgerald changed their price target from N/A to N/A for 4D Molecular Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4D Molecular Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4D Molecular Therapeutics was filed on September 23, 2024 so you should expect the next rating to be made available sometime around September 23, 2025.
While ratings are subjective and will change, the latest 4D Molecular Therapeutics (FDMT) rating was a downgraded with a price target of $0.00 to $0.00. The current price 4D Molecular Therapeutics (FDMT) is trading at is $10.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.